Lupus Nephritis: all 338 studies

Page 2 of 4. Open to participants first (131), then studies with results posted, then the rest; newest registration first within each.

• Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics AnalysisRecruitingNCT06167174
• SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney DiseaseRecruitingNCT06155604Phase 2
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusRecruitingNCT06121297Phase 1/2
• Assessment of Safety and Efficacy of SGLT2is Among LN PatientsNot yet recruitingNCT06113900Phase 1/2
• RY_SW01 Cell Injection Therapy in Active Lupus NephritisRecruitingNCT06058078Phase 2
• the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus PatientsNot yet recruitingNCT05964751
• Lupus Landmark Study: A Prospective Registry and BiorepositoryRecruitingNCT05934149
• Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus NephritisNot yet recruitingNCT05933213Phase 4
• CNCT19 Cell Injection for Refractory Systemic Lupus ErythematosusEnrolling by invitationNCT05930314Early Phase 1
• Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus ErythematosusRecruitingNCT05916781Phase 4
• Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus NephritisRecruitingNCT05863936Phase 3
• A Study of Telitacicept in Lupus NephritisRecruitingNCT05680480Phase 2
• The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LNRecruitingNCT05631717Phase 3
• Belimumab In Prevention of LNNot yet recruitingNCT05585671
• The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyRecruitingNCT05538208Phase 2
• Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorRecruitingNCT05508009Phase 1/2
• MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LNRecruitingNCT05495893Phase 4
• Disease Activity Biomarkers in Patients With Systemic Lupus ErythematosusRecruitingNCT05443516
• Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus NephritisRecruitingNCT05207358Phase 4
• VIBRANT: VIB4920 for Active Lupus NephritisRecruitingNCT05201469Phase 2
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsRecruitingNCT05039619Phase 2
• Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFRecruitingNCT04702256Phase 3
• Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 CohortRecruitingNCT04534647
• Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus NephritisRecruitingNCT04449991Not applicable
• KOrea Renal Biobank NEtwoRk System TOward NExt-generation AnalysisRecruitingNCT03929887
• Mesenchymal Stromal Cells (MSC´s) in Renal LupusRecruitingNCT03917797Phase 2
• Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem CellsRecruitingNCT03673748Phase 2
• High Quality Evidence of Chinese Lupus Nephritis (HELP)RecruitingNCT03001973
• The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus NephritisRecruitingNCT02954939Not applicable
• Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)RecruitingNCT01802034
• Study of Systemic Lupus ErythematosusRecruitingNCT00001372
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)TerminatedNCT05781750Phase 2Results posted
• Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis PatientsCompletedNCT05748925Phase 4Results posted
• Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)TerminatedNCT05540665Phase 2Results posted
• Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus NephritisTerminatedNCT05232864Phase 3Results posted
• Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)TerminatedNCT05097989Phase 2Results posted
• Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus NephritisCompletedNCT04971590Results posted
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)TerminatedNCT04564339Phase 2Results posted
• A Study of Guselkumab in Participants With Active Lupus NephritisTerminatedNCT04376827Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisActive, not recruitingNCT04221477Phase 3Results posted
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisTerminatedNCT04181762Phase 3Results posted
• Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative NephritisCompletedNCT04128579Phase 1Results posted
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus NephritisTerminatedNCT03943147Phase 2Results posted
• Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.CompletedNCT03610516Phase 2Results posted
• Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With VoclosporinCompletedNCT03597464Phase 3Results posted
• Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesCompletedNCT03453619Phase 2Results posted
• A Study of KZR-616 in Patients With SLE With and Without Lupus NephritisCompletedNCT03393013Phase 1/2Results posted
• An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus NephritisCompletedNCT03385564Phase 2Results posted
• Aurinia Renal Response in Active Lupus With VoclosporinCompletedNCT03021499Phase 3Results posted
• Aurinia Early Urinary Protein Reduction Predicts ResponseCompletedNCT02949973Phase 2Results posted
• Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus NephritisCompletedNCT02770170Phase 2Results posted
• Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721TerminatedNCT02682407Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)CompletedNCT02550652Phase 2Results posted
• Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus NephritisCompletedNCT02547922Phase 2Results posted
• Rituximab and Belimumab for Lupus NephritisCompletedNCT02260934Phase 2Results posted
• ACTHar in the Treatment of Lupus NephritisTerminatedNCT02226341Phase 4Results posted
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)TerminatedNCT02176486Phase 1Results posted
• AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)CompletedNCT02141672Phase 2Results posted
• A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus NephritisTerminatedNCT02081183Phase 3Results posted
• BIIB023 Long-Term Extension Study in Subjects With Lupus NephritisTerminatedNCT01930890Phase 2Results posted
• Efficacy and Safety Study of Abatacept to Treat Lupus NephritisTerminatedNCT01714817Phase 3Results posted
• Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 3Results posted
• BIIB023 Proof-of-Concept Study in Participants With Lupus NephritisTerminatedNCT01499355Phase 2Results posted
• A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus NephritisCompletedNCT01085097Phase 2Results posted
• Abatacept and Cyclophosphamide Combination Therapy for Lupus NephritisCompletedNCT00774852Phase 2Results posted
• Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus NephritisCompletedNCT00709722Phase 1/2Results posted
• Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kgCompletedNCT00705367Phase 1Results posted
• A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)TerminatedNCT00626197Phase 3Results posted
• The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus NephritisTerminatedNCT00573157Phase 2/3Results posted
• Etanercept for the Treatment of Lupus NephritisTerminatedNCT00447265Phase 2Results posted
• A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.TerminatedNCT00425438Phase 3Results posted
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis FlareCompletedNCT00423098Phase 2Results posted
• A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.CompletedNCT00377637Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus NephritisCompletedNCT00282347Phase 3Results posted
• The Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis PatientsActive, not recruitingNCT07823556Not applicable
• Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus NephritisActive, not recruitingNCT07678203Phase 1/2
• Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus NephritisActive, not recruitingNCT07044115Phase 1/2
• Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.CompletedNCT07031674
• A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Active, not recruitingNCT07015983Phase 2
• A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)WithdrawnNCT06984341Phase 1
• A Clinical Study of YTS109 Cell in R/R Systemic Lupus ErythematosusTerminatedNCT06943937Phase 1
• C-CAR168 CAR T Cell Therapy for Refractory Autoimmune DiseaseWithdrawnNCT06935474Phase 1/2
• S100A8 in Serum and Urine as a New Biomarker in Lupus NephritisCompletedNCT06872138
• Systemic Immune Inflammatory Index in Systemic Lupus ErythematosusCompletedNCT06796569
• Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus ActivityCompletedNCT06757725Not applicable
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)WithdrawnNCT06752876Phase 1
• Phase IIa Study for IPG11406 in Patients With Lupus NephritisCompletedNCT06717815Phase 1/2
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus ErythematosusCompletedNCT06653556Early Phase 1
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active, not recruitingNCT06581198Phase 2
• A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic DiseaseActive, not recruitingNCT06544330Phase 1
• Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)TerminatedNCT06445127
• A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus ErythematosusWithdrawnNCT06429800Phase 1
• A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)WithdrawnNCT06377228Phase 1
• KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisTerminatedNCT06342960Phase 1/2
• Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)Active, not recruitingNCT06294236Phase 1
• AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06265220Phase 1
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesActive, not recruitingNCT06255028Phase 1
• A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)WithdrawnNCT06153095Phase 1/2
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101Active, not recruitingNCT06152172Phase 1
• A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedNCT06064929Phase 1

← Lupus Nephritis overview